Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

DOI: https://doi.org/10.1097/HS9.0000000000000987

2023-10-31

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000907.].

What problem does this paper attempt to address?

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Ru Zhou,Mahboubeh Yazdanifar,Lopamudra Das Roy,Lynsey M. Whilding,Artemis Gavrill,John Maher,Pinku Mukherjee

DOI: https://doi.org/10.3389/fimmu.2020.628776

IF: 7.3

2020-12-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2019.01149.].

immunology
Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

DOI: https://doi.org/10.1097/HS9.0000000000000980

2023-10-04

HemaSphere

Abstract:[This corrects the article DOI: 10.1097/HS9.0000000000000871.].
Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Yuan Meng,Biping Deng,Luan Rong,Chuo Li,Weiliang Song,Zhuojun Ling,Jinlong Xu,Jiajia Duan,Zelin Wang,Alex H. Chang,Xiaoming Feng,Xiujuan Xiong,Xiaoli Chen,Jing Pan

DOI: https://doi.org/10.3389/fonc.2021.778039

IF: 4.7

2021-10-01

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.640166.].

oncology
Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Jun Zhou,Wenjing Zhang,Yanping Zhang,Saifang Zheng,Luting Zhou,Xiaoqun Yang,Chaofu Wang

2022-01-01

American journal of translational research

Abstract:[This corrects the article on p. 6751 in vol. 12, PMID: 33194070.].
Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Águeda Molinos-Quintana,Anna Alonso-Saladrigues,Blanca Herrero,Teresa Caballero-Velázquez,Víctor Galán-Gómez,Melissa Panesso,Montserrat Torrebadell,Javier Delgado-Serrano,Concepción Pérez de Soto,Anna Faura,Berta González-Martínez,Ana Castillo-Robleda,Cristina Diaz-de-Heredia,Antonio Pérez-Martínez,José María Pérez-Hurtado,Susana Rives,José Antonio Pérez-Simón

DOI: https://doi.org/10.3389/fimmu.2024.1373852

IF: 7.3

2024-02-07

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1280580.].

immunology
Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

DOI: https://doi.org/10.1182/blood-2016-06-725010

IF: 20.3

2016-08-18

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2015-04-639203.].
Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Hongfeng Huang,Qixia Shen,Jingyi Zhou,Xiuyan Yang,Qiuqin Cai,Jia Shen,Shi Feng,Wenqing Xie,Hong Jiang,Jianghua Chen

DOI: https://doi.org/10.3389/fimmu.2022.1052676

IF: 7.3

2022-01-01

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2022.995243.].
Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang,Lin Yang,Zheng Li,Ansel P Nalin,Haiping Dai,Ting Xu,Jia Yin,Fengtao You,Mingqing Zhu,Wenhong Shen,Guanghua Chen,Xiaming Zhu,Depei Wu,Jianhua Yu

2018-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 1083 in vol. 8, PMID: 30034945.].
Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Zhongqing Zou,Tingting Guo,Jian Cui,Wenjiao Tang,Yan Li,Fangfang Wang,Tian Dong,Yunfan Yang,Yan Feng,Matthew Ho,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.7150/jca.79561

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:[This corrects the article DOI: 10.7150/jca.53209.].

oncology
Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

DOI: https://doi.org/10.1097/BS9.0000000000000185

2024-03-07

Abstract:[This corrects the article DOI: 10.1097/BS9.0000000000000179.].
Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

DOI: https://doi.org/10.1182/blood-2016-06-723056

IF: 20.3

2016-07-28

Blood

Abstract:[This corrects the article DOI: 10.1182/blood-2008-10-184143.].
Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Editorial Office

DOI: https://doi.org/10.21037/tp-2024-02

2024-09-02

Translational Pediatrics

Abstract:Editorial Office Translational Pediatrics Submitted Jul 15, 2024. Accepted for publication Jul 25, 2024. Published online Aug 28, 2024. doi: 10.21037/tp-2024-02 Erratum to: Transl Pediatr 2023;12:1926-30. The article (1) entitled "Maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients" ( Transl Pediatr 2023;12:1926-30. doi: 10.21037/tp-23-391) unfortunately contained some mistakes in the main text on page 1929. In paragraph 14, the "event-free-survival" should be "overall survival". The OS should be EFS. The data "91%±4.4% (≤2006) versus 88%±4.3% (>2006)" should be "89%±5.1% (≤2006) versus 87%±4.6% (>2006)". The corrected content is presented as below: Survival analyses revealed that there were no significant differences in overall survival after the reassignment being 89%±5.1% (≤2006) versus 94%±3.2% (>2006). The similar trend was observed for EFS showing 89%±5.1% (≤2006) versus 87%±4.6% (>2006). The small increase in OS observed in the group of patients treated >2006 could be due to the better response of a small subset of patients that relapse. The authors apologize for these errors and state that these errors do not change the scientific conclusions of the article in any way. Click here to view the updated version of the article. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

pediatrics
Erratum: Aldenhoven M, van den Broek BTA, Wynn RF, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236-2242

DOI: https://doi.org/10.1182/bloodadvances.2017014407

2017-12-07

Abstract:[This corrects the article DOI: 10.1182/bloodadvances.2017011387.].
Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Bi-Cheng Wang,Bo-Ya Xiao,Peng-Cheng Li,Bo-Hua Kuang,Wang-Bing Chen,Pin-Dong Li,Guo-He Lin,Quentin Liu

DOI: https://doi.org/10.1155/2021/3735726

IF: 4.501

2021-02-25

Journal of Oncology

Abstract:[This corrects the article DOI: 10.1155/2020/2368164.].

oncology
Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Zhenyu Wei,Jiayu Xu,Chengkui Zhao,Min Zhang,Nan Xu,Liqing Kang,Xiaoyan Lou,Lei Yu,Weixing Feng

DOI: https://doi.org/10.3389/fimmu.2024.1379325

IF: 7.3

2024-02-08

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1273507.].

immunology
Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

DOI: https://doi.org/10.3233/BLC-219500

2021-03-19

Bladder Cancer

Abstract:[This corrects the article DOI: 10.3233/BLC-200013.].
Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Thomas Morgan Hulen,Christina Friese,Nikolaj Pagh Kristensen,Joachim Stoltenborg Granhøj,Troels Holz Borch,Marlies J W Peeters,Marco Donia,Mads Hald Andersen,Sine Reker Hadrup,Inge Marie Svane,Özcan Met

DOI: https://doi.org/10.3389/fimmu.2024.1462081

2024-07-18

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1180997.].
Author Correction: Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

J. Joseph Melenhorst,Gregory M. Chen,Meng Wang,David L. Porter,Changya Chen,McKensie A. Collins,Peng Gao,Shovik Bandyopadhyay,Hongxing Sun,Ziran Zhao,Stefan Lundh,Iulian Pruteanu-Malinici,Christopher L. Nobles,Sayantan Maji,Noelle V. Frey,Saar I. Gill,Alison W. Loren,Lifeng Tian,Irina Kulikovskaya,Minnal Gupta,David E. Ambrose,Megan M. Davis,Joseph A. Fraietta,Jennifer L. Brogdon,Regina M. Young,Anne Chew,Bruce L. Levine,Donald L. Siegel,Cécile Alanio,E. John Wherry,Frederic D. Bushman,Simon F. Lacey,Kai Tan,Carl H. June

DOI: https://doi.org/10.1038/s41586-022-05376-8

IF: 64.8

2022-12-08

Nature

Abstract:Nature - Author Correction: Decade-long leukaemia remissions with persistence of CD4+ CAR T cells

multidisciplinary sciences
Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Zhiwen Fu,Jinmei Liu,Shijun Li,Chen Shi,Yu Zhang

DOI: https://doi.org/10.1016/j.eclinm.2023.101908

IF: 15.1

2023-01-01

EClinicalMedicine

Abstract:[This corrects the article DOI: 10.1016/j.eclinm.2023.101904.][This corrects the article DOI: 10.1016/j.eclinm.2022.101795.].
Erratum: Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum.

Zhongqing Zou,Tingting Guo,Jian Cui,Wenjiao Tang,Yan Li,Fangfang Wang,Tian Dong,Yunfan Yang,Yan Feng,Matthew Ho,Li Zhang,Ling Pan,Ting Niu

DOI: https://doi.org/10.7150/jca.79561

IF: 3.9

2022-01-01

Journal of Cancer

Abstract:[This corrects the article DOI: 10.7150/jca.53209.].

Correction Notice: Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

Corrigendum: CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth

Correction Notice: Impact of T-cell Receptor Status on Mutational Landscape and Outcome in T-ALL

Corrigendum: Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL

Erratum: Evaluation of the clinicopathologic features of diffuse large B cell lymphoma after CD19-targeted CAR T-cell therapy emphasizing the potential diagnostic pitfalls.

Corrigendum: Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T Cell (Tisagenlecleucel) infusion in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia: role of B-cell monitoring

Erratum: Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219

Corrigendum: Immune Tolerance Induced by Hematopoietic Stem Cell Infusion after HLA Identical Sibling Kidney Transplantation

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum

Erratum: Sequential treatment escalation improves survival in patients with Waldenstrom macroglobulinemia

Erratum: Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood. 2009;114(10):2051-2059

Erratum to maintaining excellent outcomes: the impact of age cutoff reclassification on reduced therapy for neuroblastoma patients

Erratum: Aldenhoven M, van den Broek BTA, Wynn RF, et al. Quality of life of Hurler syndrome patients after successful hematopoietic stem cell transplantation. Blood Adv. 2017;1(24):2236-2242

Corrigendum to “Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis”

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

Erratum: Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer

Corrigendum: Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Author Correction: Decade-long leukaemia remissions with persistence of CD4 + CAR T cells

Corrigendum to “Treatment-Related Adverse Events Associated with HER2-Targeted Antibody-Drug Conjugates in Clinical Trials: a Systematic Review and Meta-Analysis” [eclinicalmedicine 55 (2022) 101795]

Erratum: Real-world data combined with studies on Regulatory B Cells for newly diagnosed Multiple Myeloma from a tertiary referral Hospital in South-Western China: Erratum.